VEGFA and medullary thyroid gland carcinoma: The antitumoral effect of 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.0612 mM concentrations of Bevacizumab, a specific VEGF antibody, on human medullary thyroid cancer cell line TT, was evaluated with the real-time cell analysis system (xCELLigence System).